Arrhythmia Disorders News

PHILADELPHIA — Postural orthostatic tachycardia syndrome is a common cardiac complication in COVID-19 survivors and research is ongoing as to optimal treatments, a speaker said during the Heart in Diabetes CME Conference.

Rocket Pharmaceuticals announced that the FDA has granted fast track and orphan drug designations to its adeno-associated virus-based gene therapy for the treatment of plakophilin-2-related arrhythmogenic cardiomyopathy.

AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release.

Use of a standardized protocol identified candidates for same-day discharge after catheter ablation for atrial fibrillation and also predicted procedural outcomes, researchers reported at Heart Rhythm 2023.

Abiomed is recalling specific left ventricular assist device sets used for people with cardiomyopathy due to customer complaints about purge fluid leaking from the sidearm of the pump, according to an FDA press release.

In high-risk patients undergoing ablation for ventricular tachycardia, use of a mechanical circulatory support device did not improve clinical outcomes, researchers reported at Heart Rhythm 2023.

An extravascular implantable cardioverter defibrillator was associated with effective treatment and low complication rates at 12 to 18 months, researchers reported at Heart Rhythm 2023.

Healio and Cardiology Today have compiled the top cardiology headlines of May 2023.

Among patients who received an implantable cardioverter defibrillator, nearly half received appropriate therapy within 7 years, indicating the benefit of the technology in guideline-indicated patients, researchers reported.

A leadless, ultrasound-based endocardial pacing system was able to deliver cardiac resynchronization therapy to patients unable to be implanted with conventional CRT devices, researchers reported.